Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

E.U.R.L. PHARMACIE RUMMENS : revenue, balance sheet and financial ratios

E.U.R.L. PHARMACIE RUMMENS is a French company founded 15 years ago, specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé. Based in MUZILLAC (56190), this company of category PME shows in 2021 a net income positive of 309 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-04-25

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - E.U.R.L. PHARMACIE RUMMENS (SIREN 528085749)
Indicator 2021
Revenue N/C
Net income 309 197 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2021, E.U.R.L. PHARMACIE RUMMENS generates positive net income of 309 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2021) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

309 197 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 53%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 58%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2021) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

53.055%

Financial autonomy (2021) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

58.49%

Asset age ratio (2021) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

63.3%

Solvency indicators evolution
E.U.R.L. PHARMACIE RUMMENS

Sector positioning

Debt ratio
53.05 2021
2021
Q1: 29.04
Med: 85.54
Q3: 208.43
Good

In 2021, the debt ratio of E.U.R.L. PHARMACIE RUMMENS (53.05) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
58.49% 2021
2021
Q1: 25.89%
Med: 44.41%
Q3: 64.18%
Good

In 2021, the financial autonomy of E.U.R.L. PHARMACIE RUMMENS (58.5%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 249.54. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2021) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

249.542

Liquidity indicators evolution
E.U.R.L. PHARMACIE RUMMENS

Sector positioning

Liquidity ratio
249.54 2021
2021
Q1: 139.2
Med: 190.68
Q3: 259.61
Good

In 2021, the liquidity ratio of E.U.R.L. PHARMACIE RUMMENS (249.54) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.

Working capital requirement (WCR) and payment terms

Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 58 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 680 days. Excellent situation: suppliers finance 622 days of the operating cycle (retail model).

Operating WCR (2021) ?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released
Positive = financing needed

0 €

Customer credit (2021) ?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good
45-60j : Average
> 60j : Long

58 j

Supplier credit (2021) ?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow

680 j

Inventory turnover (2021) ?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover

0 j

WCR and payment terms evolution
E.U.R.L. PHARMACIE RUMMENS

Positioning of E.U.R.L. PHARMACIE RUMMENS in its sector

Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé

Valuation estimate

Based on 220 transactions of similar company sales in 2021, the value of E.U.R.L. PHARMACIE RUMMENS is estimated at 3 546 618 € (range 2 280 493€ - 5 478 410€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2021
220 transactions
2280k€ 3546k€ 5478k€
3 546 618 € Range: 2 280 493€ - 5 478 410€
NAF 5 année 2021

Valuation method used

Net Income Multiple
309 197 € × 11.5x = 3 546 618 €
Range: 2 280 493€ - 5 478 411€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)

Compare E.U.R.L. PHARMACIE RUMMENS with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de détail de produits pharmaceutiques en magasin spécialisé

Frequently asked questions about E.U.R.L. PHARMACIE RUMMENS

What is the revenue of E.U.R.L. PHARMACIE RUMMENS ?

The revenue of E.U.R.L. PHARMACIE RUMMENS is not publicly disclosed (confidential accounts filed with INPI).

Is E.U.R.L. PHARMACIE RUMMENS profitable?

Yes, E.U.R.L. PHARMACIE RUMMENS generated a net profit of 309 k€ in 2021.

Where is the headquarters of E.U.R.L. PHARMACIE RUMMENS ?

The headquarters of E.U.R.L. PHARMACIE RUMMENS is located in MUZILLAC (56190), in the department Morbihan.

Where to find the tax return of E.U.R.L. PHARMACIE RUMMENS ?

The tax return of E.U.R.L. PHARMACIE RUMMENS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does E.U.R.L. PHARMACIE RUMMENS operate?

E.U.R.L. PHARMACIE RUMMENS operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.